{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:44:02Z","timestamp":1788871442628,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.contraception.2011.05.015","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T22:27:01Z","timestamp":1311460021000},"page":"177-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bioequivalence study of an oral contraceptive containing ethinylestradiol\/drospirenone\/levomefolate calcium relative to ethinylestradiol\/drospirenone and to levomefolate calcium alone"],"prefix":"10.1016","volume":"85","author":[{"given":"Hartmut","family":"Blode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Klipping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Trummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"Diefenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2011.05.015_bb0005","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3109\/14767051003678234","article-title":"Micronutrients and women of reproductive potential: required dietary intake and consequences of dietary deficiency or excess. Part I \u2014 folate, vitamin B12, vitamin B6","volume":"23","author":"Simpson","year":"2010","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.contraception.2011.05.015_bb0010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.5694\/j.1326-5377.1989.tb136723.x","article-title":"Dietary folate as a risk factor for neural-tube defects: evidence from a case\u2013control study in Western Australia","volume":"150","author":"Bower","year":"1989","journal-title":"Med J Aust"},{"key":"10.1016\/j.contraception.2011.05.015_bb0015","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJM199212243272602","article-title":"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation","volume":"327","author":"Czeizel","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2011.05.015_bb0020","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1001\/jama.1988.03410210053035","article-title":"Periconceptional use of multivitamins and the occurrence of neural tube defects","volume":"260","author":"Mulinare","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2011.05.015_bb0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(80)90886-7","article-title":"Possible prevention of neural-tube defects by periconceptional vitamin supplementation","volume":"1","author":"Smithells","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.05.015_bb0030","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jama.1993.03500100055027","article-title":"Periconceptional folic acid exposure and risk of occurrent neural tube defects","volume":"269","author":"Werler","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2011.05.015_bb0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0140-6736(91)90133-A","article-title":"Prevention of neural tube defects: results of the Medical Research Council Vitamin Study","volume":"338","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.05.015_bb0040","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJM199911113412006","article-title":"Neural-tube defects","volume":"341","author":"Botto","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2011.05.015_bb0045","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/S0140-6736(01)07104-5","article-title":"Quantifying the effect of folic acid","volume":"358","author":"Wald","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.05.015_bb0050","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(06)68582-6","article-title":"Folic acid: a public-health challenge","volume":"367","author":"Eichholzer","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.05.015_bb0055","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1001\/jama.1995.03530210052030","article-title":"Folate levels and neural tube defects. Implications for prevention","volume":"274","author":"Daly","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2011.05.015_bb0060","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/0003-4819-150-9-200905050-00009","article-title":"Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement","volume":"150","author":"Preventive Services Task Force","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.contraception.2011.05.015_bb0065","author":"European Surveillance of Congenital Anomalies (EUROCAT)"},{"key":"10.1016\/j.contraception.2011.05.015_bb0070","first-page":"362","article-title":"Spina bifida and anencephaly before and after folic acid mandate \u2014 United States, 1995\u20131996 and 1999\u20132000","volume":"53","author":"Centers for Disease Control and Prevention (CDC)","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.contraception.2011.05.015_bb0075","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/bmj.330.7491.574","article-title":"Preventing neural tube defects in Europe: population based study","volume":"330","author":"Busby","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2011.05.015_bb0080","author":"Food and Drug Administration"},{"key":"10.1016\/j.contraception.2011.05.015_bb0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ajcn\/84.1.156","article-title":"Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age","volume":"84","author":"Lamers","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.contraception.2011.05.015_bb0090","article-title":"Folate status after 24 weeks' treatment with a folate-fortified version of YAZ","author":"Sampson-Landers","year":"2010"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2011.05.015_bb0095","first-page":"60","article-title":"Changes in folate levels following a 24-week co-administration of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg","volume":"15","author":"Diefenbach","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.05.015_bb0100","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ajcn\/79.3.473","article-title":"Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women","volume":"79","author":"Lamers","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.contraception.2011.05.015_bb0105","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/11532990-000000000-00000","article-title":"Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics","volume":"49","author":"Pietrzik","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2011.05.015_bb0110","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/ajcn\/77.3.658","article-title":"Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study","volume":"77","author":"Venn","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.contraception.2011.05.015_bb0115","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/jn\/132.11.3353","article-title":"Increases in blood folate indices are similar in women of childbearing age supplemented with [6S]-5-methyltetrahydrofolate and folic acid","volume":"132","author":"Venn","year":"2002","journal-title":"J Nutr"},{"key":"10.1016\/j.contraception.2011.05.015_bb0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.05.015_bb0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.contraception.2009.01.016","article-title":"Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24\/4-day regimen","volume":"80","author":"Hernadi","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.05.015_bb0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.contraception.2007.11.003","article-title":"Efficacy and safety of 3 mg drospirenone\/20 mcg ethinylestradiol oral contraceptive administered in 24\/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial","volume":"77","author":"Koltun","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.05.015_bb0135","first-page":"143","article-title":"A combined oral contraceptive containing 3-mg drospirenone\/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment","volume":"82","author":"Lucky","year":"2008","journal-title":"Cutis"},{"key":"10.1016\/j.contraception.2011.05.015_bb0140","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/AOG.0b013e318187e1c5","article-title":"Treatment of acne using a 3-milligram drospirenone\/20-microgram ethinyl estradiol oral contraceptive administered in a 24\/4 regimen: a randomized controlled trial","volume":"112","author":"Maloney","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.05.015_bb0145","first-page":"837","article-title":"A randomized controlled trial of a low dose combined oral contraceptive containing 3 mg drospirenone plus 20 mcg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings, and subject self-assessment","volume":"8","author":"Maloney","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.contraception.2011.05.015_bb0150","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.contraception.2005.08.021","article-title":"Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation","volume":"72","author":"Pearlstein","year":"2005","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.05.015_bb0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","article-title":"Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder","volume":"106","author":"Yonkers","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.05.015_bb0160","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/ajcn\/86.5.1414","article-title":"Calculation of red blood cell folate steady-state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women of childbearing age","volume":"86","author":"Pietrzik","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.contraception.2011.05.015_bb0165","first-page":"e4","article-title":"Study on circadian variation in folate pharmacokinetics","volume":"12","author":"Ahn","year":"2005","journal-title":"Can J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2011.05.015_bb0170","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/AOG.0b013e3181b46f54","article-title":"Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives","volume":"114","author":"Cronin","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.05.015_bb0175","first-page":"5","article-title":"Use of supplements containing folic acid among women of childbearing age \u2014 United States, 2007","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.contraception.2011.05.015_bb0180","author":"European Surveillance of Congenital Anomalies (EUROCAT) Special Report"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411002514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411002514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:09:39Z","timestamp":1757880579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782411002514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0010782411002514"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2011.05.015","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioequivalence study of an oral contraceptive containing ethinylestradiol\/drospirenone\/levomefolate calcium relative to ethinylestradiol\/drospirenone and to levomefolate calcium alone","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2011.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}